Key Highlights
- Cash, cash equivalents and investments came to USD 153.4 million at the close of June 2026, against USD 48.3 million at the start of the year, a level management says covers operations into the first half of 2028.
- The second-quarter net loss narrowed to USD 18.0 million, or USD 0.13 per share, from USD 25.9 million, or USD 0.49 per share, a year earlier.
- Research and development expense dropped to USD 13.1 million from USD 18.0 million, while general and administrative costs eased to USD 5.1 million from USD 5.5 million.
- Topline data covering 80 patients from the Phase 2 ASPEN-09-Breast study of evorpacept in HER2-positive metastatic breast cancer are expected in mid-2027, and ALX2004 initial safety readings are due in the second half of 2026.
Points Investors Should Track at ALX Oncology Holdings Inc. (NASDAQ:ALXO) Before Its Release
ALX Oncology (NASDAQ:ALXO) has its third quarter 2026 release scheduled for November 16, 2026, which covers the period ended September 30, 2026. As a clinical-stage company it has no product revenue, so the discussion centres on operating costs, net loss and cash. Market data cited publicly place its Market Capitalisation at roughly USD 124 million on October 14, 2026, with 138.28 million shares in issue at USD 0.89 each. The second-quarter loss of USD 18.0 million and cash balance of USD 153.4 million serve as reference points.
Operating Cost Cuts, Non-GAAP Loss and Stock Compensation at ALX Oncology (NASDAQ:ALXO)
Second-quarter operating expenses came to USD 18.0 million, versus USD 26.6 million a year before, which is a calculated fall of about 32%. Research and Development dropped by USD 4.9 million, mostly because legacy trials cost less. Non-GAAP net loss totalled USD 14.3 million, down from USD 20.6 million, with share-based pay at USD 2.7 million. Across the half-year, the GAAP loss reached USD 35.9 million, or USD 0.30 a share, versus USD 56.7 million. The weighted average share count was 135,639,684, and beyond the runway statement through the first half of 2028 management has issued no numeric financial guidance.
Debt Facility Terms, Accumulated Deficit and Trial Risks at ALX Oncology (NASDAQ:ALXO)
At June 30, 2026, ALX Oncology (NASDAQ:ALXO) reported USD 160.6 million of assets, USD 24.4 million of liabilities and USD 136.2 million of stockholders' equity. The accumulated deficit reached USD 758.7 million. A USD 10 million Loan was refinanced with HSBC Ventures USA in June 2026, and further draws of up to USD 20 million are possible through June 2028. The ceiling of that arrangement is USD 50 million, although USD 10 million of it carries no commitment. Principal hazards are trial results, funding needs beyond 2028, dilution from share sales and rivalry among CD47-directed treatments.
Where Things Stand
ALX Oncology Holdings Inc. (NASDAQ:ALXO) approaches its November 16, 2026 report after a year of spending discipline and a repaired balance sheet. The second-quarter loss of USD 18.0 million compares with USD 25.9 million previously, while operating costs dropped to USD 18.0 million and cash climbed to USD 153.4 million, stretching the runway into the first half of 2028. Future value depends on clinical progress: ALX2004 initial safety data are expected in the second half of 2026, while ASPEN-09-Breast topline results from 80 patients are due in mid-2027. The third quarter release should indicate whether spending holds near current levels.





_11_19_2026_18_29_00_678569.jpg)
Please wait processing your request...